AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02011672 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: regular milk
Study NCT00032006 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Study NCT02789020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: This test will be performed at baseline and one year.
Study NCT02789020 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: functional Magnetic Resonance Imaging
Description: This test will be performed at baseline and one year.
Study NCT00032006 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT03990701 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 11C-Metomidate PET/CT Scan
Description: 11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre
Study NCT04209400 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sci-B-Vac®
Description: Sci-B-Vac® vaccine-10 μg of HBsAg, intramuscular injection of 10 μg/ml
Study NCT04209400 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B®
Description: Engerix-B® vaccine-20 μg of HBsAg, intramuscular injection of 20 μg/ml
Study NCT02808507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active TB case finding
Description: Active TB case finding (ACF) refers to any number of strategies used to identify individuals with active TB disease, outside of passive case finding. In passive case finding, individuals with symptoms present at health centers for diagnosis. In active case finding, the health system makes an effort to identify TB cases before they present passively.
Study NCT03862495 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: C. trachomatis and N. gonorrhoeae
Description: In vitro nucleic acid amplification test for the qualitative detection of Chlamydia trachomatis and/or Neisseria gonorrhea in patient specimens utilizing amplification of target DNA by the Polymerase Chain Reaction (PCR) and nucleic acid hybridization for the detection of C. trachomatis and N. gonorrhoeae.
Study NCT02789020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional Magnetic Resonance Imaging
Description: This test will be performed at baseline and one year.
Study NCT02789020 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical Function Performance Test
Description: This test will be performed at baseline and one year.
Study NCT02789020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Function Performance Test
Description: This test will be performed at baseline and one year.
Study NCT03771352 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RxSight RxLAL
Description: The patients will be assessed for 6 months
Study NCT03438903 — intervention group
Intervention type: DEVICE
Intervention: Repeat exams of OCT device
Description: All 2 consecutive OCT examinations were performed by 1 experienced technician, in the order of SD-OCT and SS-OCT. The interval was 10 minutes between examinations by each OCT devices
Study NCT00445315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00868554
Description: 300 mg BID
Study NCT03862495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 1g administered as a single oral dose
Study NCT02689206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1278863 matching Placebo
Description: GSK1278863 matching placebo will be supplied as a round, biconvex, 10 mm white film coated tablet.
Study NCT01239277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protein
Description: 20g protein
Study NCT03862495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partner notification and treatment
Description: Pregnant women who test positive for Chlamydia will also be suggested to take Azithromycin home to treat their spouses
Study NCT00445315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00868554
Description: 450 mg BID
Study NCT00445315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00868554
Description: 100 mg BID
Study NCT00437203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00477736
Description: * Escalating doses of PF-00477736 will be administered intravenously on Days 2 and 9 and gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).~* If a patient is administered Cycle 0 - only PF-0047736 will be administered intravenously on Days 1 and 8 of a 21-day cycle for patients who have a 3-hour infusion and Days 1 and 8 of a 14-day cycle for patients who have a 24-hour infusion.
Study NCT00445315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00868554
Description: 300 mg TID
Study NCT00437203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).
Study NCT02733679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be given orally, regularly for eight weeks. Dose starts at 500mg once daily for one week, increasing by 500mg per week, to final dose of 1000mg twice daily.
Study NCT02733679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin will be given orally, regularly for eight weeks. Dose starts at 500mg once daily for one week, increasing by 500mg per week, to final dose of 1000mg twice daily.
Study NCT02733679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone will be given orally, regularly for eight weeks. Dose starts at 15mg once daily and after one week increases to 30mg once daily.
Study NCT02733679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone will be given orally, regularly for eight weeks. Dose starts at 15mg once daily and after one week increases to 30mg once daily.
Study NCT04785937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound and Magnetic Resonance
Description: liver ultrasound (US), including shear wave elastography (SWE) with liver stiffness measurement and US- fatty liver indicator (US-FLI), and a multiparametric unenhanced liver magnetic resonance examination including MR spectroscopy (MRS), Proton Density Fat Fraction (PDFF) and T2\* measurement with Multiecho technique, T1 mapping with Inversion Recovery method, and Intravoxel Incoherent Motion diffusion weighted imaging (IVIM-DWI), measuring different parameters.
Study NCT02661945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near focus with narrow band imaging
Study NCT00445315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03285386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Priming exercise
Description: All participants will perform a bout of high-intensity priming exercise for 6 minutes, 10 minutes prior to undertaking an exhaustive exercise test on four separate occasions.
Study NCT03285386 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Exercise
Description: All participants will perform 3 minutes of baseline cycling prior to undertaking an exhaustive exercise test on four separate occasions.
Study NCT01239277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protein and carbohydrate
Description: 20g protein and 20g carbohydrate
Study NCT01239277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protein and leucine
Description: 20g protein, 2.5g leucine
Study NCT02534012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paravertebral block
Description: Bilateral nerve stimulator-guided PVB is performed while patients are in lateral decubitis position. An intervertebral line is drawn at the appropriate levels and the injection site is marked 2.5 cm lateral to the midline on both sides. After aseptic preparation of the skin, 0.3 mL 2% lidocaine is infiltrated at the injection sites. A 22-G nerve stimulation needle (Stimuplex, B.Braun, Melsungen, Germany) is advanced 1-2 cm perpendicularly to the skin using a nerve stimulating current of 2.5-5.0 mA, while closely watching for contractions of the abdominal muscles. The tip of the needle is adjusted to continue to produce muscle contractions while reducing the stimulating current to approximately 0.5-0.6 mA. Depending on patient weight, 3-5 mL of the local anaesthetic mixture is injected at each injection site.
Study NCT02534012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Anesthesia is induced with 1 µg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg nimbex (cisatracurium). Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 µg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen.
Study NCT02534012 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Major abdominal surgery
Study NCT00707538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS747158
Description: 2 IV injection of \~11 mCi (total) F-18 labeled compound
Study NCT00084604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00084604 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00084604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00084604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Correlative studies
Study NCT00084604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01415297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKP-1339
Description: NKP-1339 is administered as a 30-90 minute IV infusion (based on volume to be infused) on days 1, 8, and 15 of a 28 day cycle.
Study NCT01301053 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Current UVA intensive care insulin protocol
Description: Current UVA intensive care insulin protocol used for insulin management for 12 hours
Study NCT01301053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current UVA intensive care insulin protocol with brakes
Description: Current UVA intensive care insulin protocol for insulin management with the addition of brakes which reduces insulin administration based on continuous glucose monitoring data between hourly reference glucose data to reduce episodes of hypoglycemia (blood glucose \<70 mg/dl)and severe hypoglycemia (blood glucose\<50 mg/dl).
Study NCT04539054 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ENGN Shred
Description: ENGN Shred is a multi-ingredient pre-workout supplement.
Study NCT04539054 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutricost caffeine powder
Description: Caffeine powder.
Study NCT04539054 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Crystal Light
Description: Non-caloric Crystal Light matched for the pre-workout in terms of flavor and consistency.
Study NCT02794883 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV
Study NCT02794883 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies
Study NCT02794883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies
Study NCT02794883 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Procedure
Description: Undergo surgical tumor resection
Study NCT02794883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgical tumor resection
Study NCT02794883 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tremelimumab
Description: Given IV
Study NCT02794883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study NCT03035864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF
Description: Eye Drop 20 μg/mL
Study NCT03035864 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Eye Drop
Study NCT02578134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: US-guided percutaneous electrolysis
Description: US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the symptomatic insertion of the plantar fascia
Study NCT02578134 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham US-guided percutaneous electrolysis
Description: The acupuncture needle will be inserted into the symptomatic plantar fascia but no galvanic electrical current will be applied, the equipment will be turn off. Patients will be blinded to the application of galvanic electrical current.
Study NCT03996681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylcantharidimide tablets
Description: Drug: methylcantharidimide tablets~Methylcantharidimide is a single molecule drug used for the treatment of primary liver cancer.~Procedure: TACE~Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor.
Study NCT03271242 — intervention group
Intervention type: OTHER
Intervention: Systematic implementation support
Description: Implementation support is offered by implementation trainers visiting each clinical unit every two weeks for 6 months and then monthly for 12 months. Support is given only for the practice randomly assigned to support. The aim is to engage leaders and clinicians in identifying and overcoming implementation barriers, and in building systems to support and sustain implementation. Implementation trainers from all sites are trained together and meet every 2-3 month with leaders of the implementation training for supervision, mutual discussion, and exchange of experiences. At the start of the implementation, leaders and clinicians were also invited to a workshop on the practice they have been randomly assigned to receive support for. Toolkits are made available on a website.
Study NCT03271242 — intervention group
Intervention type: OTHER
Intervention: No implementation support
Description: No implementation support is offered to clinical units for the practice randomly assigned to no implementation support, of the two practices (of the four practices in the project) that unit has chosen to implement.
Study NCT00935506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Tablets, Oral, 75 mg, Once daily, 8 days
Study NCT00935506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Tablets, Oral, 325 mg, Once daily, 8 days
Study NCT01894763 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-expandable metal stent
Description: Placement of a self-expandable metal stent in the esophagus
Study NCT02552771 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral repair with leaflet preservation
Description: Placing man-made fibers (sutures) to more securely connect the mitral leaflets to the papillary muscles (muscles located in the ventricle).
Study NCT02552771 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral repair with leaflet resection
Description: Removing one or both of the mitral leaflets that flop or bulge back.
Study NCT00303732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 (everolimus)
Study NCT00303732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787 (vatalanib)
Study NCT03256097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XDP sound processing strategy - Period 0
Description: XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
Study NCT00533910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 550mg BID rifaximin for 8 weeks
Study NCT00533910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: same as the experimental arm
Study NCT03256097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XDP sound processing strategy - Period 1
Description: XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
Study NCT03256097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VG sound processing strategy - Period 1
Description: Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
Study NCT03256097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XDP sound processing strategy - Period 2
Description: XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
Study NCT03256097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VG sound processing strategy - Period 2
Description: Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend
Study NCT03256097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XDP sound processing strategy - Period 3
Description: XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
Study NCT03256097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VG sound processing strategy - Period 3
Description: Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend
Study NCT03256097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voice Track
Description: Voice Track is a cochlear implant noise cancellation system which is designed to reduce the adverse effect of background noise on speech perception through cochlear implants
Study NCT04334512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Treatment with hydroxychloroquine
Study NCT04334512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Treatment with azithromycin
Study NCT04334512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C
Description: Treatment with vitamin C
Study NCT04334512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Treatment with vitamin C
Study NCT04334512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Treatment with vitamin D
Study NCT04334512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Treatment with vitamin D
Study NCT04334512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Zinc
Description: Treatment with Zinc
Study NCT04334512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Treatment with Zinc
Study NCT04549415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: patients were divided into 2 groups: 1st group was on lifestyle modification (LSM), 2nd group on regimen LSM+ metformin (1000 g b.i.d) during 12 months
Study NCT04549415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle modification
Description: Lifestyle modification Standard Principles
Study NCT03979872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MC1R Genetic Testing
Description: \[See arm/group descriptions\]
Study NCT03979872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skin Cancer Education
Description: \[See arm/group descriptions\]
Study NCT02129283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation training
Description: End-of-life simulation training. The simulation training will include training with standardized patients (actors) using 9 essential skills for communication and interpersonal relationships. The control group will have no training.
Study NCT04625231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Shared-Decision Making Tool
Description: Patients received a short video presentation on pain management, use of over the counter medication, side effects of opioids and over-the-counter medications and ability to choose the amount of opioid pills up to the standard care amount.
Study NCT01327664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Study NCT01119313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS 41002
Description: LAS 41002, once daily
Study NCT03979872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Cancer Education
Description: \[See arm/group descriptions\]
Study NCT03979872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UV Photo
Description: \[See arm/group descriptions\]